Comparison of zolpidem and zaleplon exposures in Texas, 1998-2004

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 69, Issue 20, 2006, Pages 1883-1892

  Forrester, Mathias B ^a  

^a TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZALEPLON; ZOLPIDEM;

ADULT; ARTICLE; ATAXIA; CONFUSION; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG EXPOSURE; DRUG INTOXICATION; FEMALE; GROUPS BY AGE; HALLUCINATION; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RESIDENT; SEX DIFFERENCE; SLURRED SPEECH; STATISTICAL ANALYSIS; TACHYCARDIA; UNITED STATES; VOMITING;

ACETAMIDES; ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; POISON CONTROL CENTERS; PYRIDINES; PYRIMIDINES; RETROSPECTIVE STUDIES; SEX FACTORS; TEXAS;

ATAXIA;

EID: 33748473376     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390600631763     Document Type: Article

References (5)

1. Barbera, J., and Shapiro, C. 2005. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Safety 28:301-318.
2. Holm, K. J., and Goa, K. L. 2000. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59:865-889.
3. Israel, A. G., and Kramer, J. A. 2002. Safety of zaleplon in the treatment of insomnia. Ann. Pharmacother. 36:852-859.
4. Kurta, D. L., Myers, L. B., and Krenzelok, E. P. 1997. Zolpidem (Ambien): A pediatric case series. J. Toxicol. Clin. Toxicol. 35:453-457.
5. Sanger, D. J. 2004. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18(suppl. 1):9-15.